NL-OMON41146撤回不适用
Combo Bio-Engineered Sirolimus Eluting Stent Placement Long-Term Healing Pattern Assessment by Optical Coherence Tomography - COMBO Healing
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. The patient must be *18 and * 80 years of age;
- •2. Device and procedural success at the index procedure;
- •3. The Patient is willing to comply with specified follow-up evaluations;
- •4. The Patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided written informed consent, approved by the appropriate Medical Ethics Committee (MEC), Institutional Review Board (IRB), or Human Research Ethics Committee (HREC).
排除标准
- •1. Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of childbearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test;
- •2. Impaired renal function (serum creatinine >2.0 mg/dL or 177 *mol/l) or on dialysis;
- •3. Platelet count <100,000 cells/mm3 or >700,000 cells/mm3 or a WBC<3,000 cells/mm3;
- •4. Patient has other medical illness (e.g., cancer, known malignancy, or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with
- •5. a limited life expectancy (i.e., less than 1 year);
- •6. Patient has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, prasugrel, stainless steel alloy, sirolimus, everolimus and/or contrast sensitivity that cannot be adequately pre-medicated;
- •7. Patient has received any organ transplant or is on a waiting list for any organ transplant;
- •8. Any significant medical condition, which in the Investigator*s opinion may interfere with the patient*s optimal participation in the study;
- •9. Currently participating in another investigational drug or device study or patient in inclusion in another investigational drug or device study during follow-up;;Angiographic exclusion criteria
- •10. Patients treated for in-stent restenosis of the index procedure Combo stent during follow-up;
- •11. Patients treated for in-segment stenosis of the index procedure Combo stent during follow-up;
- •12. Patients treated for a bifurcation lesion with a 2 stent strategy at the index procedure during follow-up;
- •13. Patients treated in a bypass graft at the index procedure;
- •14. Patients with >1 overlapping Combo stent at the index procedure;
- •15. Patient with unsuitable anatomy for OCT (tortious, heavily calcified, small distal stent).
研究者
相似试验
招募中
不适用
Sirolimus-coated balloon versus drug-eluting stent in native coronary vesselsNL-OMON54209Fondazione Ricerca e Innovazione Cardiovascolare, No profit organization315
尚未招募
不适用
Sirolimus-coated balloon versus drug-eluting stent in native coronary vesselsNL-OMON22515Fondazione Ricerca e Innovazione Cardiovascolare ETS1,130
已完成
不适用
Sirolimus Eluting Angioplasty Balloon for In-Stent REstenosis (SABRE) Trialcoronary heartdiseaseIn-stent restenosis10011082NL-OMON41496Caliber Therapeutics, Inc.10
Unknown
不适用
Biomime Stent in All-comers PCI Patients RegistryCoronary Artery DiseaseNCT02398955Azienda Ospedaliero Universitaria Maggiore della Carita250
已完成
不适用
BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) European Angiography Studycoronary artery diseasecoronary artery stenosis10011082NL-OMON47919Medinol Lid.49